XBiotech Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $4.0M | $18.4M |
| Gross profit | — | — | $0 | $3.4M | $12.6M |
| Operating income | -$55.7M | -$42.5M | -$37.5M | -$34.5M | -$25.1M |
| Operating expenses | — | $42.5M | $37.5M | $37.8M | $37.7M |
| Cost of revenue | — | — | $0 | $651,000 | $5.8M |
| Cash from operations | -$39.9M | -$31.0M | -$18.7M | -$14.8M | $69.4M |
| Capital expenditure | $289,000 | $1.3M | $362,000 | $585,000 | $3.5M |
| Free cash flow | -$40.2M | -$32.3M | -$19.1M | -$15.4M | $65.9M |
| Share repurchases | — | $0 | $14,000 | $0 | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $150.1M | $199.1M | $226.6M | $246.1M | $275.2M |
| Total liabilities | $9.7M | $16.8M | $7.8M | $5.7M | $5.8M |
Shares outstanding 30.5M · Free float 99.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.